Zeltia has expanded the clinical programme for its investigational multiple myeloma treatment Aplidin.

The Spanish drugmaker says its PharmaMar subsidiary has initiated a Phase I trial looking at Aplidin (plitidepsin) in combination with Johnson & Johnson’s Velcade (bortezomib) and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Its primary endpoint of this trial is to determine the recommended dose of Aplidin in combination with the two other mainstay treatments and to evaluate its efficacy.
The trial will be conducted in six centres in Spain and France and will recruit 30 patients. The study is part of PharmaMar’s strategy to develop Aplidin as an earlier treatment option; the compound is also in a Phase III study for patients with multiple myeloma after the third line of treatment.